Curated News
By: NewsRamp Editorial Staff
May 05, 2026

NRx Pharmaceuticals Launches First Commercial Manufacturing of Preservative-Free Ketamine

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NRx Pharmaceuticals initiates commercial manufacturing of preservative-free ketamine, positioning for FDA approval and market advantage by summer 2026.
  • NRx started first commercial manufacturing order of ketamine, supported by stability data from multiple registration batches and a successful audit.
  • NRx advances ketamine treatment for suicidal depression, potentially offering new hope to patients with limited options.
  • NRx's ketamine targets suicidal depression and PTSD, with Fast Track and Breakthrough Therapy designations from the FDA.

Impact - Why it Matters

This development is crucial because it brings a potential new treatment option for suicidal depression and chronic pain closer to market. Preservative-free ketamine could offer a safer, more effective alternative for patients who have not responded to traditional therapies, addressing a significant gap in mental health care.

Summary

NRx Pharmaceuticals (NASDAQ: NRXP) has announced a significant milestone: the initiation of its first commercial manufacturing order for preservative-free ketamine. This move comes in anticipation of potential approval under the Generic Drug User Fee Act (GDUFA) in summer 2026. The decision is backed by robust stability data from multiple registration batches and a successful third-party manufacturing audit. This development positions the company to address critical unmet needs in mental health treatment, particularly for suicidal depression, chronic pain, and PTSD.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform. The company is advancing two key candidates: NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has received Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression, while NRX-101 has been awarded Breakthrough Therapy Designation for suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100, with an application for the Commissioner’s National Priority Voucher Program.

This news was disseminated by NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which delivers a range of services including access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit the NetworkNewsWire website.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NRx Pharmaceuticals Launches First Commercial Manufacturing of Preservative-Free Ketamine

blockchain registration record for this content.